NCT02549261 - Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

December 31, 2015

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

nimotuzumab

the nimotuzumab treatment: 200mg/w weekly, for 16 weeks. A treatment:nimotuzumab for 3 levels (100mg/w, 200mg/w, 400mg/w, weekly, for 16 weeks).

DRUG

Cisplatin

Concurrent Chemotherapy,50mg/m2 (d1,d8),4 weeks/cycle, for 2 cycles. the consolidation chemotherapy: Cisplatin: 50mg/m2 (d1,d8)4 weeks/cycle, for 2 cycles.

DRUG

Etoposide

"Concurrent Chemotherapy, Cisplatin: Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles.~the consolidation chemotherapy:Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles."

RADIATION

radiotherapy

the tolerance trial of treatment A and B of treatment;95％PTV,60-66Gy/30-33/fraction,6-7weeks.

Trial Locations (1)

Unknown

Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing